Risankizumab is a monoclonal antibody used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. In this test-specific episode of the "Answers From the Lab" podcast, Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new risankizumab assay (Mayo ID: RISA) measures the drug's concentration in blood to guide optimal patient treatment.

"Therapeutic drug monitoring is routinely used to assess loss of response to therapy and proactively manage patients taking biologics. It has become standard of care in Crohn's disease," Dr. Willrich says. "But anyone taking risankizumab for any condition could be recommended to have this test."

The mass spectrometry-based test can quantify risankizumab from 1 to 100 micrograms per milliliter in serum samples. "That's expected to cover trough and peak concentrations expected in all the conditions that risankizumab is prescribed for," Dr. Willrich says. Additional testing for risankizumab antibodies is under development.

"If patients do not meet therapeutic drug concentrations, providers can decide to personalize the treatment regimen or discontinue the drug," Dr. Willrich says.

Listen to learn more about Mayo Clinic Laboratories' new risankizumab assay.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

RISA   | Risankizumab, Serum

The latest

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

View MoreView Less